The October 20, 2015, article by Masters et al, entitled “Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update” (J Clin Oncol 33: 3488-3515, 2015), contained an error.
On page 3489, under the “First-Line Treatment for Patients” in the Bottom Line box, the fifth summary bullet incorrectly stated: “With ALK gene rearrangements: crizotinib is recommended (evidence quality: intermediate; strength of recommendation: moderate).”
This should have said “With ALK gene rearrangements: crizotinib is recommended (evidence quality: high; strength of recommendation: strong),” which is the same evidence quality and strength of recommendation as on page 3503.
The online version has been corrected in departure from the print. The authors apologize for the error.